Transparency Market Research Report Added "Hypertrophic Cardiomyopathy Therapeutics Market" to its database.

Albany, NY -- (SBWire) -- 01/19/2016 --Transparency Market Research, in its latest report, states that the global hypertrophic cardiomyopathy therapeutics market is anticipated to witness tepid growth over the next seven years. Thoroughly analyzing the performance of the market from 2015 to 2023, the report - titled "Hypertrophic Cardiomyopathy Therapeutics Market - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends, and Forecast, 2015 - 2023" – reveals that the global hypertrophic cardiomyopathy therapeutics market is forecast to rise from a value of US$1.2 bn in 2014 to US$1.4 bn in 2023, registering a 1.40% CAGR during that time.

Browse the full Hypertrophic Cardiomyopathy Therapeutics Market: (By Drug Class: Beta Adrenergic Blocking Agents, Calcium Channel Blocker, Antiarrhythmic Agents, and Anticoagulants) - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends, and Forecast, 2015 - 2023 report at http://www.transparencymarketresearch.com/hypertrophic-cardiomyopathy-therapeutics-market.html

The rising prevalence of chronic cardiovascular diseases, increased awareness about hypertrophic cardiomyopathy, and the growing demand for effective treatments options are the key factors fueling the hypertrophic cardiomyopathy therapeutics market. However, technological upgradation in devices such as pacemakers and defibrillators hampers the demand for hypertrophic cardiomyopathy drugs.

In order to provide readers with a clear understanding of the structure, scope, and dynamics of the hypertrophic cardiomyopathy therapeutics market, the report segments the overall market based on drug class and geography.

On the basis of drug class, the hypertrophic cardiomyopathy therapeutics market is categorized into calcium channel blockers, anticoagulants, beta adrenergic blocking agents, and antiarrhythmic agents. By revenue, calcium channel blockers held the largest share in 2014 and this trend is likely to continue through 2023 with the segment expanding at a 1.80% CAGR during that time. By demand, beta adrenergic blocking agents dominated the market given that they are the first choice for treatment of obstructive and non-obstructive hypertrophic cardiomyopathy.

Request A Sample Of This Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=7553

On the basis of geography, the global hypertrophic cardiomyopathy therapeutics market is segmented into North America, Europe, Asia Pacific, and Rest of the World. Accounting for over 30.0% of the overall market in 2014, the US emerged as the leading regional segment of the hypertrophic cardiomyopathy therapeutics market, with Europe following suit. Both these markets are fueled by the rising obese population, availability of modern healthcare infrastructure, high awareness about hypertrophic cardiomyopathy, and sedentary lifestyle among the youth. Asia Pacific is projected to be the fastest developing regional segment of the hypertrophic cardiomyopathy therapeutics market by 2023 owing to development of healthcare infrastructure, increased prevalence of the cardiac ailments and complications, and growing awareness.

An interesting feature of the report on the hypertrophic cardiomyopathy therapeutics market is its assessment of the vendor landscape. Major competitors are identified and examined in detail. Some of the key players competing in the global hypertrophic cardiomyopathy therapeutics market are Gilead Sciences, Inc., Astra Zeneca plc, Novartis AG, Mylan N.V., Concordia Healthcare Corp., Teva Pharmaceutical Industries Ltd., Pfizer, Inc., Sanofi S.A., and Merck & Co., Inc. These competitors are profiled in the report based on attributes such as company and financial overview, product portfolio, recent developments, and business strategies.

Read Full Press Release: http://www.transparencymarketresearch.com/pressrelease/global-hypertrophic-cardiomyopathy-therapeutics-market.htm

Global Hypertrophic Cardiomyopathy Therapeutics, by Drug Class
Beta Adrenergic Blocking Agents
Calcium Channel Blockers
Antiarrhythmic Agents
Anticoagulants
Global Hypertrophic Cardiomyopathy Therapeutics, by Geography
North America
U.S.
Canada
Europe
U.K.
Germany
Rest of Europe
Asia Pacific
India
Japan
Rest of Asia Pacific
Rest of the World
Latin America
Middle East
Africa

About Transparency Market Research (TMR)
Transparency Market Research (TMR) is a U.S.-based provider of syndicated research, customized research, and consulting services. TMR's global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Contact us:
Mr. Sudip S
Transparency Market Research
90 State Street,
Suite 700,
Albany
NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/